Provided by Tiger Trade Technology Pte. Ltd.

Veru Inc.

2.50
+0.01500.60%
Volume:130.36K
Turnover:324.17K
Market Cap:42.54M
PE:-4.26
High:2.53
Open:2.52
Low:2.46
Close:2.48
52wk High:7.33
52wk Low:2.05
Shares:17.05M
Float Shares:15.48M
Volume Ratio:0.49
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5854
EPS(LYR):-1.5517
ROE:-64.54%
ROA:-54.03%
PB:1.50
PE(LYR):-1.61

Loading ...

Veru CEO Steiner Joins Canaccord Genuity Growth Investors Conference Fireside Chat

Reuters
·
Jul 30

Veru completes enrollment in PLATEAU clinical study

TIPRANKS
·
Jul 27

Veru Completes Enrollment in Phase 2 Obesity Study

MT Newswires Live
·
Jul 27

Veru Completes Enrollment in Phase 2b Plateau Trial of Enobosarm with Semaglutide in Older Obesity Patients

Reuters
·
Jul 27

Veru Announces Full Enrollment for Phase 2B Plateau Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

THOMSON REUTERS
·
Jul 27

Veru - Interim Analysis Results for Phase 2B Plateau Trial Expected in Q1 2027

THOMSON REUTERS
·
Jul 27

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

GlobeNewswire
·
Jul 07

Veru - Enters Sales Agreement with Oppenheimer & Co. and Canaccord Genuity on July 2, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 03

Veru - to Offer and Sell up to $21.8 Mln of Common Stock Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
Jul 03

Veru Enters At-the-market Equity Sales Agreement for up to $21.8 Million Stock Offering

Reuters
·
Jul 03

Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge

MT Newswires Live
·
Jun 05

Veru pact with Novo ‘significant event,’ says Canaccord

TIPRANKS
·
Jun 05

Veru Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 05

Veru announces clinical supply agreement with Novo Nordisk

TIPRANKS
·
Jun 05

Veru enters clinical supply deal with Novo Nordisk for enobosarm-Wegovy obesity trial

Reuters
·
Jun 04

Veru - Enters Clinical Supply Agreement With Novo Nordisk for Phase 2B Plateau Study - SEC Filing

THOMSON REUTERS
·
Jun 04

Veru - to Provide Novo Nordisk With Insights and Updates on Obesity Trial Design - SEC Filing

THOMSON REUTERS
·
Jun 04

Veru - Grants Novo Nordisk Right of First Negotiation for Enobosarm in Combination With Any Novo's Glp-1 Products

THOMSON REUTERS
·
Jun 04

Soccer-FIFA rolls out global initiative to boost female player health and performance

Reuters
·
Jun 02

Veru : Oppenheimer Cuts Target Price to $24 From $25

THOMSON REUTERS
·
May 15